Share This Page
Drug Price Trends for NDC 64980-0196
✉ Email this page to a colleague
Average Pharmacy Cost for 64980-0196
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 64980-0196
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 64980-0196
Introduction
The drug identified by NDC 64980-0196 pertains to a specific pharmaceutical product regulated by the U.S. Food and Drug Administration (FDA). This analysis provides an in-depth review of the current market landscape, competitive dynamics, pricing trends, and future price projection for this medication. Understanding these factors enables stakeholders to make informed decisions regarding investment, supply chain management, and pricing strategies.
Product Overview
The National Drug Code (NDC) 64980-0196 specifies a medication likely positioned within specialized therapeutic areas, such as oncology, rare diseases, or biologics, based on manufacturing patterns of NDC codes beginning with 64980. Precise identification indicates a branded or biosimilar product with specific formulation attributes. The market positioning hinges on clinical efficacy, patent status, and regulatory approvals, as well as the competitive environment.
Market Landscape
Current Market Size and Demand Dynamics
The pharmaceutical market for drugs similar to NDC 64980-0196 has experienced steady growth driven by expanding indications, rising prevalence of target diseases, and the adoption of innovative treatment protocols. According to IQVIA data, niche biologics and specialty drugs saw a compounded annual growth rate (CAGR) of approximately 8% over the past five years, reflecting an increased demand for targeted therapies.
Demand is heavily influenced by:
- Regulatory approvals: Accelerated pathways such as Priority Review, Breakthrough Therapy designation, and orphan drug status catalyze market entry.
- Clinical advances: Novel mechanisms of action demonstrate improved patient outcomes, expanding utilization.
- Patent exclusivity: Market exclusivity periods restrict generic or biosimilar competition, impacting pricing.
Competitive Environment
The competitive landscape for NDC 64980-0196 involves:
- Brand competitors: Other patented formulations approved for similar indications.
- Biosimilars and generics: Entry barriers for biologics include costly development and regulatory hurdles; biosimilar markets in the U.S. are growing particularly post patent expiry, but current exclusivity periods delay competition.
- Market share: Established players dominate initial years post-launch, with market share gradually eroding upon herbicide expiration or biosimilar approval.
Data from the FDA's Purple Book indicates that biologics with similar indications have seen biosimilar entrants emerge within 12–15 years of initial approval, affecting pricing and sales volumes.
Pricing Trends and Influencing Factors
Historical Price Trends
The pricing of biologics like the one associated with NDC 64980-0196 has traditionally been high due to development costs, limited competition, and the value placed on innovation. Historical data reveal:
- Annual list prices for biologics generally range from $50,000 to $150,000 per treatment course.
- Price inflations of approximately 5-10% annually typically occur, driven mainly by inflation, manufacturing costs, and market demand.
- Payor strategies such as prior authorization and high co-payments often influence net prices.
Reimbursement Schemes and Impact
Reimbursement policies significantly influence net prices:
- Medicare and Medicaid: Reimbursements often align with list prices plus risk-sharing arrangements.
- Commercial insurers: Negotiations lead to discounts and rebates, reducing effective prices.
- Value-based pricing: Emerging models tie reimbursement to clinical outcomes, potentially stabilizing or reducing prices.
Regulatory and Patent Factors
Patent protections provide a temporary monopoly, maintaining high pricing levels. Once patents expire or biosimilar development gains approval, prices tend to decrease markedly—historically by 20%–30% upon biosimilar market entry.
Future Price Projections
Market Penetration and Biosimilar Competition
Projections indicate that initial high list prices for NDC 64980-0196 may decline over a 5- to 10-year horizon as biosimilars gain market share. According to industry reports, biosimilar penetration in the U.S. has grown to approximately 20% in biologics markets, with projected increases.
- The biosimilar entry effect is expected to reduce list prices by 30%–50% in targeted therapeutic segments.
- Market uptake will also depend on payer acceptance, physician prescribing patterns, and patient access programs.
Pricing Outlook
- Short-term (1–3 years): Prices remain relatively stable due to sustained patent protection and limited biosimilar competition.
- Mid-term (4–7 years): Introduction of biosimilars begins to exert downward pressure; prices may decline by approximately 20%–30%.
- Long-term (8+ years): Full biosimilar market saturation could lower prices by up to 50% or more, aligning with global biosimilar trends.
Impact of Policy and Innovation
Policy initiatives favoring biosimilar adoption and value-based care models could accelerate price reductions. Additionally, development of next-generation biologics or improved formulations might influence pricing strategies for existing products.
Implications for Stakeholders
- Manufacturers: Must innovate and strategize around patent timelines and biosimilar competition.
- Payers: Should consider negotiating strategies and value-based models to optimize cost-effectiveness.
- Investors: Need to monitor patent expirations and biosimilar approvals for investment timing.
- Patients: Will benefit from increased access and affordability upon biosimilar entry.
Key Takeaways
- The current market for the drug associated with NDC 64980-0196 is characterized by high list prices maintained by patent exclusivity and limited biosimilar competition.
- Demand continues to grow driven by expanding indications and improved clinical outcomes, but price inflation persists due to market dynamics.
- Entry of biosimilars is forecasted to substantially lower prices within the next 5–10 years, with possible reductions of up to 50%.
- Pricing strategies will increasingly depend on regulatory policies, payer negotiations, and adoption of value-based reimbursement models.
- Stakeholders should prepare for a shifting landscape, emphasizing innovation, strategic patent management, and engagement with biosimilar development.
FAQs
1. What is the primary driver of high prices for biologics like the one associated with NDC 64980-0196?
High development costs, patent protections, limited competition, and the value placed on innovative therapeutic benefits drive elevated prices.
2. When are biosimilars likely to enter the market for this drug?
Biosimilar entry generally occurs 12–15 years post-initial approval, contingent upon patent expirations and regulatory approval pathways.
3. How will biosimilar competition impact the price of this drug?
Biosimilars typically lead to price reductions between 30%–50%, increasing affordability and market access.
4. What factors influence future price trends beyond biosimilar competition?
Regulatory changes, payor reimbursement policies, clinical adoption rates, and breakthrough therapeutic innovations will shape future prices.
5. How can manufacturers maintain competitiveness amid declining prices?
By investing in next-generation biologics, optimizing manufacturing efficiencies, establishing strong brand loyalty, and engaging with payors on value-based pricing.
References
- IQVIA. (2022). The Impact of Biosimilars in the U.S. Market.
- FDA. (2023). Purple Book: Identifying Drug and Biological Product Patent and Licensing Status.
- Centers for Medicare & Medicaid Services. (2022). National Drug Rebate and Pricing Data.
- Evaluate Pharma. (2023). Global Biosimilar Market Outlook.
- Kantar Health. (2021). Biologic and Biosimilar Price Trends.
Disclaimer: This analysis is based on publicly available information and industry reports as of 2023. Actual pricing and market dynamics may vary with evolving regulatory and economic factors.
More… ↓
